StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
6886.TWO$47.95+4.24%
Fair $47.95+0.0%

6886.TWO

Far East Bio-Tec Co., Ltd.

Consumer Defensive / Packaged FoodsTaipei Exchange

$47.95

+1.95 (+4.24%)

Fairly Valued+0.0%Fair Value $47.95Fund rank 25/100 · Data gapFallback financials|
SA 35/D
F-Score: 5/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-11.5M · quality 43.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 12/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

35/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 6886.TWOLocal privado en este navegador · Far East Bio-Tec Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.5B

P/E

25.5x

↑

EV/EBITDA

13.2x

↑

ROE

10.2%

↑

Gross Margin

50.5%

↑

Debt/Equity

0.10

↓
52-Week Range$48
$42$52

TradingView lightweight chart

6886.TWO price, volumen y niveles de valoración

Último $47.95Periodo -33.1%
Fair value: $47.95

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+1.9%

FCF CAGR

—

FCF margin

-2.9%

FCF / Net income

-0.19x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $401.7M · net income $60.0M · FCF $-11.5M

2022-FY → 2025-FY

Gross margin

50.5%-6.0% pts

Operating margin

17.1%-11.7% pts

Net margin

14.9%-8.9% pts

FCF margin

-2.9%-28.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$401.7M$401.7M$387.7M$306.2M$379.7M
Net Income$60.0M$60.0M$52.5M$27.4M$90.7M
EBITDA$98.9M$98.9M$90.3M$49.1M$126.6M
EPS——1.700.903.28
Gross Margin50.5%50.5%48.2%46.5%56.5%
Operating Margin17.1%17.1%16.5%9.3%28.8%
Net Margin14.9%14.9%13.5%8.9%23.9%
Balance Sheet
Debt/Equity0.100.100.130.080.11
Cash Flow
Free Cash Flow$-11.5M$-11.5M$-10.2M$-17.6M$95.6M
Returns
ROE10.2%10.2%10.2%5.6%21.0%
Valuation
P/E25.5125.5128.2451.53—
EV/EBITDA13.2313.2313.3123.28—
P/B2.592.592.742.88—
Growth & Yield
Revenue Growth3.6%3.6%26.6%-19.4%—
EPS Growth——87.9%-72.4%—
Dividend Yield2.1%2.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +9.2%

Total return

+9.2%

Start / end P/E

n/dx → n/dx

EPS bridge

1.70 → n/d

Residual

+7.1%

EPS growthn/d
Multiple reratingn/d
Dividend+2.1%
Residual / FX / buybacks / cross-term+7.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.